Vericel to Present at the SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25, 2021

Rhea-AI Summary

Vericel Corporation (NASDAQ:VCEL) announced that its President and CEO, Nick Colangelo, will present a company overview at the SVB Leerink 10th Annual Global Healthcare Conference. The virtual presentation is scheduled for February 25, 2021, at 10:00 a.m. Eastern Time. A live webcast will be accessible through the Investor Relations section of the Vericel website. Vericel specializes in advanced therapies in sports medicine and severe burn care, marketing products like MACI® and Epicel®.

CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the SVB Leerink 10^th Annual Global Healthcare Conference. The conference is being conducted in a virtual format and the presentation will take place on Thursday, February 25, 2021, at 10:00 a.m. Eastern Time.

A live webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI^® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel^® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid^®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company’s website at www.vcel.com.

Epicel^® and MACI^® are registered trademarks of Vericel Corporation. NexoBrid^® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2021 Vericel Corporation. All rights reserved.

Investor Contacts:
Chad Rubin
Solebury Trout
crubin@troutgroup.com 
+1 646-378-2947

FAQ

What is the date and time of Vericel's presentation at the SVB Leerink Conference?

Vericel's presentation is scheduled for February 25, 2021, at 10:00 a.m. Eastern Time.

Where can I watch the live webcast of the Vericel presentation?

The live webcast of Vericel's presentation can be accessed via the Investor Relations section of Vericel's website.

What products does Vericel Corporation market?

Vericel markets MACI® and Epicel®, advanced therapies for sports medicine and severe burn care.

Who is presenting for Vericel at the conference?

Nick Colangelo, the President and CEO of Vericel Corporation, will present at the conference.

What is the significance of MACI® and Epicel® for Vericel?

MACI® is used for cartilage repair, and Epicel® serves as a permanent skin replacement for severe burns, highlighting Vericel's role in advanced medical therapies.